| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 02/19/2003 | CN1101818C Novel water-soluble c-ring analogues of 20(s)-campothecin |
| 02/19/2003 | CN1101816C Substituted purine derivatives, processes for their prepn. their use, and compsns. comprising them |
| 02/19/2003 | CN1101693C Externally applied Chinese medicine |
| 02/19/2003 | CN1101677C Pharmaceutical injection solution contg. taxol |
| 02/19/2003 | CA2420065A1 Methods for indentifying specifically cleavable peptides and use of such peptide sequences |
| 02/18/2003 | WO2002016329A1 Novel phenylalanine derivatives |
| 02/18/2003 | US6521759 Aminothiazole inhibitors of cyclin dependent kinases |
| 02/18/2003 | US6521757 Preparation of fused polycyclic alkaloids by ring closure of azomethine ylides, novel compounds thereof and their use as chemotherapeutic agents |
| 02/18/2003 | US6521755 Process for preparing 10,11-methanobenzosuberane derivatives |
| 02/18/2003 | US6521749 GL50 nucleic acids and uses therefor |
| 02/18/2003 | US6521746 Leukotoxin polypeptide fused to gonadotropin releasing hormone/factor multimer; increased immunogenicity |
| 02/18/2003 | US6521657 Indole derivatives which are agonists of the progesterone receptor and useful for treatment of carcinoma and adenocarcinomas of uterine leiomyomata, endometriosis or polycystic ovary syndorme in a mammal |
| 02/18/2003 | US6521654 Substituted imidazolidine derivatives, their preparation, their use and pharmaceutical preparations including them |
| 02/18/2003 | US6521646 Integrin inhibitors |
| 02/18/2003 | US6521620 Suppressing tumors, especially breast cancers; antiproli-ferative agents; arthritis, vascular restenosis, psoriasis and angiogenesis; extremely low cytotoxicity |
| 02/18/2003 | US6521616 Administering taurolidine, taurultam, or a biologically active derivative; induces tumor cell death by apoptosis. |
| 02/18/2003 | US6521608 Pulsed administration that avoids development of severe symptomatic or life threatening hypercalcemia |
| 02/18/2003 | US6521606 Matrix metalloproteinase inhibitors |
| 02/18/2003 | US6521604 Compounds containing boron for energy-filtering transmission electron microscopy and for boron neutron-capture therapy |
| 02/18/2003 | US6521602 Anti-neoplastic compositions and uses thereof |
| 02/18/2003 | US6521593 Using antagonists of integrins such as alpha v beta 3 and alpha v beta 5; inhibiting angiogenesis and vitronectin and tenascin mediated cell adhesion; inducing apoptosis |
| 02/18/2003 | US6521456 Gene therapy for cancer; treating viral infections, nervous system disorders, graft rejection, and monogenic or polygenic disorders |
| 02/18/2003 | US6521437 Human sphingosine lyase polypeptides |
| 02/18/2003 | US6521422 Fhm, a novel member of the TNF ligand supergene family |
| 02/18/2003 | US6521417 Incubating permeabilized cells expressing mutant kinase with radiolabeled analog; cytolysis, separation by sodium dodecyl sulfate polyacrylamide gel electrophoresis |
| 02/18/2003 | US6521407 Methods for determining chemosensitivity of cancer cells based upon expression of negative and positive signal transduction factors |
| 02/18/2003 | US6521262 Solid instant-release forms of administration and process for producing the same |
| 02/18/2003 | US6521230 CD25 binding molecules |
| 02/18/2003 | US6521210 Diagnosing a malignancy in in situ tissue. |
| 02/18/2003 | CA2420042A1 Carboxylic acid derivatives, processes for the preparation thereof and pharmaceutical agents comprising the same as active ingredient |
| 02/18/2003 | CA2351004C Formulation |
| 02/18/2003 | CA2264508C Substituted benzocycloheptapyridine derivatives useful for inhibition of farnesyl protein transferase |
| 02/18/2003 | CA2051520E Use of folic acid and its derivatives for reducing the toxicity of gar-transformylase inhibitors |
| 02/14/2003 | WO2002018326A1 Novel propenohydroxamic acid derivatives |
| 02/14/2003 | CA2423733A1 Novel propenohydroxamic acid derivatives |
| 02/13/2003 | WO2003012441A1 Method for detecting modulators of notch signalling |
| 02/13/2003 | WO2003012432A1 Erythropoietin and anti-tumor necrosis factor alpha combination therapy |
| 02/13/2003 | WO2003012122A2 Crystallized structure of type iv collagen nc1 domain hexamer |
| 02/13/2003 | WO2003012112A1 Methylation resistant vectors |
| 02/13/2003 | WO2003012111A2 Conjugates for the modulation of immune responses |
| 02/13/2003 | WO2003012105A2 Vegf isoform |
| 02/13/2003 | WO2003012104A1 Novel g protein-coupled receptor protein and dna thereof |
| 02/13/2003 | WO2003012093A2 Regulator of calcineurin |
| 02/13/2003 | WO2003012086A1 Antigen presenting cells, method for their preparation and their use for cancer vaccines |
| 02/13/2003 | WO2003012085A1 Antigen presenting cells, method for their preparation and their use for cancer vaccines |
| 02/13/2003 | WO2003012072A2 Monoclonal antibodies to activated erbb family members and methods of use thereof |
| 02/13/2003 | WO2003012051A2 Inhibitor of dna methylation |
| 02/13/2003 | WO2003012045A2 Hybrid proteins with neuregulin heparin-binding domain for targeting to heparan sulfate proteoglycans |
| 02/13/2003 | WO2003011911A1 Substance specific to pd-1 |
| 02/13/2003 | WO2003011910A2 Anti-ssrp-1 monoclonal antibodies and hybridomas producing said antibodies |
| 02/13/2003 | WO2003011909A1 Binding agents with differential activity |
| 02/13/2003 | WO2003011907A2 Receptor, the use thereof, and mouse antibodies |
| 02/13/2003 | WO2003011903A2 Identification of specific tumor antigens by means of the selection of cdna libraries with sera |
| 02/13/2003 | WO2003011902A1 Identification of specific tumour antigens by selection of cdna libraries with sera |
| 02/13/2003 | WO2003011898A2 Synthetic or natural peptides binding protein phosphatase 2a, identification method and uses |
| 02/13/2003 | WO2003011896A1 Peptides having antiangiogenic activity |
| 02/13/2003 | WO2003011895A2 Compositions and methods for modulation of immune responses |
| 02/13/2003 | WO2003011878A2 Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
| 02/13/2003 | WO2003011873A2 Natural marine source phospholipids comprising flavonoids, polyunsaturated fatty acids and their applications |
| 02/13/2003 | WO2003011870A1 Gonadotropin-releasing hormone receptor antagonists |
| 02/13/2003 | WO2003011868A1 Thienopyrimidinediones and their use in the modulation of autoimmune disease |
| 02/13/2003 | WO2003011860A2 2-(3,5-BIS-TRIFLUOROMETHYL-PHENYL)-N-[6-(1,1-DIOXO-1λ6-THIOMORPHOLIN-4-YL)-4-(2-METHYL OR 4-FLUORO-2-METHYL SUBSTITUTED)PHENYL-PYRIDIN-3-YL]-N-METHYL-ISOBUTYRAMIDE |
| 02/13/2003 | WO2003011858A1 Substituted isoindoles and e use thereof |
| 02/13/2003 | WO2003011855A2 Pyrazole-derived kinase inhibitors and uses thereof |
| 02/13/2003 | WO2003011854A1 Pyrazole-derived kinase inhibitors and uses thereof |
| 02/13/2003 | WO2003011851A2 Aromatic hydroxamic acid derivatives useful as hdac inhibitors |
| 02/13/2003 | WO2003011842A1 Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation |
| 02/13/2003 | WO2003011841A1 1,2,4-triazin-3,5-diones as gonadotropin-releasing hormone receptor (gnrh) antagonists |
| 02/13/2003 | WO2003011839A1 1,3,5-triazine-2,4,6-triones, preparation and use as gonadotropin-releasing hormone receptor antagonists |
| 02/13/2003 | WO2003011838A1 Tyrosine kinase inhibitors |
| 02/13/2003 | WO2003011837A1 Tyrosine kinase inhibitors |
| 02/13/2003 | WO2003011836A1 Tyrosine kinase inhibitors |
| 02/13/2003 | WO2003011833A1 Indazole or indole derivatives, their use in human medicine and more particularly in cancerology |
| 02/13/2003 | WO2003011832A1 Quinoline derivatives and use thereof as antitumor agents |
| 02/13/2003 | WO2003011808A1 Retinoid derivatives with antiangiogenic, antitumoral and proapoptotic activities |
| 02/13/2003 | WO2003011345A1 Lipid constructs as therapeutic and imaging agents |
| 02/13/2003 | WO2003011342A2 Targeted polymeric delivery systems |
| 02/13/2003 | WO2003011339A1 Composition for epigallocatechin gallate |
| 02/13/2003 | WO2003011336A2 Liposomes prepared from the extractable lipids from a mycobacterium |
| 02/13/2003 | WO2003011332A1 Methods relating to improved polyepitope vaccination strategies |
| 02/13/2003 | WO2003011331A2 Materials and methods relating to improved vaccination strategies |
| 02/13/2003 | WO2003011330A1 Membrane vesicles of biological fluid sampled in vivo, their preparation and use in stimulating an immune response |
| 02/13/2003 | WO2003011317A1 Modulators of notch signalling for use in immunotherapy |
| 02/13/2003 | WO2003011315A1 Composition for inhibiting tyrosine kinase activity of src proteins |
| 02/13/2003 | WO2003011314A2 Use of lhrh-antagonists for the improvement of t-cell mediated immunity |
| 02/13/2003 | WO2003011313A1 Osteogenic growth oligopeptides as stimulants of hematopoiesis |
| 02/13/2003 | WO2003011304A1 Modulation of insulin-regulated aminopeptidase (irap)/angiotensin iv (at4) receptor activity |
| 02/13/2003 | WO2003011302A1 Androgen receptor modulators and methods of use thereof |
| 02/13/2003 | WO2003011293A2 Pyridinone and pyridazinone derivatives as gonadotropin-releasing hormone receptor antagonists |
| 02/13/2003 | WO2003011288A1 Novel imidazolidine derivatives, their preparation and their use as vla-4 antagonists |
| 02/13/2003 | WO2003011287A1 Pyrazolon derivatives as inhibitors of gsk-3 |
| 02/13/2003 | WO2003011285A1 BENZIMIDAZO[4,5-f]ISOQUINOLINONE DERIVATIVES |
| 02/13/2003 | WO2003011280A1 Use of vitamin e succinate and antiandrogen combination |
| 02/13/2003 | WO2003011279A1 (-)-olivil as antioxidant |
| 02/13/2003 | WO2003011277A2 Methods to mobilize progenitor/stem cells |
| 02/13/2003 | WO2003011268A1 (+)-cycloolivil as antioxidant obtained from stereospermum personatum |
| 02/13/2003 | WO2003011262A2 Use of 2-alkoxyphenyl-substituted imidazotriazinones for the treatment of diseases associated with cgmp regulated processes |
| 02/13/2003 | WO2003011252A1 Pharmaceutical composition comprising lipids comprising a polar and a nonpolar moiety |
| 02/13/2003 | WO2003011230A2 Modified reoviral therapy |
| 02/13/2003 | WO2003011226A2 Products and drug delivery vehicles |